Company: RGBP
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0001641172-25-022884
Chunk: 25

Company: Regen BioPharma Inc
Filing Date: 2025-08-11
Form: 10-Q
Item: Part II, Item 2
Chunk 25
---
Item
2. Unregistered Sales of Equity Securities and Use of Proceeds

On
June 10, 2025 Regen Biopharma, Inc.(“ Company”} issued 10,000,000 common shares (“ Shares”) to David R. Koos, the
Company’s Chief Executive Officer. The Shares were issued in settlement of $50,000 salary accrued but unpaid earned by David Koos
for services rendered pursuant to that employment agreement entered into by and between the Company and David Koos on February 10, 2015
and to which David Koos and the Company were bound between February 11, 2025 and January 22, 2020.

The
Shares were issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended (the “ Act”). No underwriters were
retained to serve as placement agents for the sale. The shares were sold directly through our management. No commission or other consideration
was paid in connection with the sale of the shares. There was no advertisement or general solicitation made in connection with this Offer
and Sale of Shares. A legend was placed on the certificate that evidences the Shares stating that the Shares have not been registered
under the Act and setting forth or referring to the restrictions on transferability and sale of the Shares.

On
July 28, 2025 Regen Biopharma, Inc. (the “ Company”) entered into a securities purchase agreement (the “ Purchase Agreement”)
with CFI Capital LLC (“ CFI”), pursuant to which CFI purchased a 6% convertible promissory Note (the “ Note”) from
the Company in the principal amount of $130,000 of which $13,000 was retained by CFI through an Original Issue Discount. The Note is
due and payable on July 28, 2026.

The
Holder of this Note is entitled, at its option, at any time after the 6th monthly anniversary of this Note, to convert all or any amount
of the principal face amount of this Note then outstanding into shares of the Company’s common stock (the “ Common Stock”)
at a price (“ Conversion Price”) for each share of Common Stock equal to 60% of the lowest trading price of the Common Stock
as reported on the OTC Markets on which the Company’s shares are then traded or any exchange up-on which the Common Stock may be
traded in the future (the “ Exchange”), for the